Revvity

About Revvity

Revvity operates in the Other / Uncategorized space and is among the firms Bracken expects to track at SNMMI 2026.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• FierceBiotech · 2026-11-26
  Revvity appoints new Chief Medical Officer ahead of pivotal trial
  Coverage notes the company's growing footprint in the radioligand therapy space.
• BioPharma Reporter · 2026-08-05
  Revvity signs supply agreement to support late-stage trials
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Reuters Health · 2026-01-24
  Revvity expands cyclotron capacity to meet Lu-177 demand
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Endpoints News · 2026-02-19
  Revvity announces Phase II readout for lead theranostic candidate
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.